Vaxcyte (PCVX) Cash & Equivalents (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Cash & Equivalents data on file, last reported at $260.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $260.8 million, down 24.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $260.8 million (down 24.8% YoY), and the FY2025 annual result was $174.0 million, down 55.15% from the prior year.
• Cash & Equivalents rose to $260.8 million in Q1 2026 per PCVX's latest filing, from $174.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.1 billion in Q3 2024 and troughed at $174.0 million in Q4 2025.
• A 5-year average of $432.0 million and a median of $380.5 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents surged 1109.91% in 2022, then sank 73.24% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $834.7 million in 2022, then tumbled by 52.38% to $397.5 million in 2023, then slipped by 2.41% to $387.9 million in 2024, then sank by 55.15% to $174.0 million in 2025, then soared by 49.95% to $260.8 million in 2026.
• Business Quant data shows PCVX's Cash & Equivalents at $260.8 million in Q1 2026, $174.0 million in Q4 2025, and $281.1 million in Q3 2025.